secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001213900-25-002070
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals enrolls first patient in expanded access study of tafenoquine for persistent babesiosis
--------------------------------------------------------------------------------

- First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.
- Prior case series in Clinical Infectious Diseases reported 80% cure rate with tafenoquine plus SOC in five high-risk patients.
- Company estimates cumulative U.S. accessible market for ARAKODA (tafenoquine) in babesiosis may exceed 400,000 patients through Dec 2035.
- Tafenoquine is FDA-approved for malaria prophylaxis (ARAKODA) but not proven effective or approved for babesiosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/0001213900-25-002070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/ea0227197-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-002070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer